

Glenmark Pharmaceuticals Limited
Statement of unaudited financial results for the quarter ended 30 June, 2018 (Rs.In Millions)

| | Particulars [Refer notes below] | Standalone (Ind AS) | | | |
|------|--|--|---|--|---------------------------------------|
| | | Quarter ended 30/06/2018 (Unaudited) | Quarter ended 31/03/2018 (Audited) [refer note 10] | Quarter ended 30/06/2017 (Unaudited) | Year ended 31/03/2018 (Audited) |
| I | Revenue from operations | | | | |
| | (a) Net sales | 15,632.28 | 15,063.27 | 15,109.26 | 60,960.52 |
| | (b) Other operating income | 551.79 | 1,614.18 | 368.52 | 3,358.32 |
| | Total revenue from operations | 16,184.07 | 16,677.45 | 15,477.78 | 64,318.84 |
| II | Other income | 1,736.49 | 442.98 | 425.88 | 1,804.22 |
| III | Total income (I + II) | 17,920.56 | 17,120.43 | 15,903.66 | 66,123.06 |
| IV | Expenses | | | | |
| | (a) Cost of materials consumed | 5,147.65 | 5,312.54 | 5,000.21 | 20,385.67 |
| | (b) Purchase of stock-in-trade | 746.72 | 632.69 | 693.06 | 2,881.77 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (172.13) | 347.33 | (109.34) | 518.47 |
| | (d) Employee benefits expense | 2,296.89 | 2,323.30 | 2,077.68 | 10,219.21 |
| | (e) Finance costs | 551.71 | 507.22 | 457.37 | 1,908.98 |
| | (f) Depreciation and amortisation expense | 334.17 | 298.18 | 299.41 | 1,182.04 |
| | (g) Other expenses | 4,061.97 | 4,758.48 | 4,286.75 | 16,838.67 |
| | Total expenses (IV) | 12,966.98 | 14,179.74 | 12,705.14 | 53,934.81 |
| V | Profit/(loss) before exceptional items and tax (III - IV) | 4,953.58 | 2,940.69 | 3,198.52 | 12,188.25 |
| VI | Exceptional items | - | - | - | - |
| VII | Profit/(loss) before tax (V - VI) | 4,953.58 | 2,940.69 | 3,198.52 | 12,188.25 |
| VIII | Tax expense : | | | | |
| | Current tax | 1,070.08 | 733.52 | 682.31 | 2,706.77 |
| | Deferred tax | (90.41) | (7.95) | (192.17) | (661.99) |
| IX | Profit/(loss) for the period (VII - VIII) | 3,973.91 | 2,215.12 | 2,708.38 | 10,143.47 |
| X | Other comprehensive income | | | | |
| | A (i) Items that will not be reclassified to profit or loss | 25.10 | 36.41 | (8.60) | (10.20) |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | (8.77) | (12.60) | 2.98 | 3.53 |
| | B (i) Items that will be reclassified to profit or loss | - | - | - | - |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - |
| XI | Total comprehensive income | 3,990.24 | 2,238.93 | 2,702.76 | 10,136.80 |
| XII | Total comprehensive income attributable to: | | | | |
| | - Non-controlling interests | - | - | - | - |
| | - Owners of the Company | 3,990.24 | 2,238.93 | 2,702.76 | 10,136.80 |
| XIII | Other equity | - | - | - | 103,632.24 |
| XIV | Earning per share (EPS) | | | | |
| | (of Re 1/- each) (not annualised) | | | | |
| | Basic EPS (in Rupees) | 14.08 | 7.85 | 9.60 | 35.95 |
| | Diluted EPS (in Rupees) | 14.08 | 7.85 | 9.60 | 35.95 |



Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

